Artificial Intelligence (AI) in Respiratory Diseases Market
Advances in artificial intelligence are changing the way respiratory diseases are diagnosed and managed, promising significant improvements in patient care. As technology evolves, the integration of AI into respiratory healthcare is expected to drive significant market growth and innovation through 2030. Let us explore the current market size, key players, emerging trends, and important segments shaping this dynamic field.
The expected expansion of artificial intelligence in the respiratory diseases market
The market for AI applications in respiratory diseases is expected to expand significantly, reaching a value of $10.19 billion by 2030. This growth corresponds to a constant compound annual growth rate (CAGR) of 5.0%. Several factors are contributing to this upward trajectory, including increasing demand for personalized respiratory therapies, increased adoption of AI-based clinical decision support systems, broader use of remote monitoring technologies for chronic respiratory patients, and a stronger focus on preventive lung disease. In addition, breakthroughs in AI-based medical imaging play a crucial role in accelerating market development. Key trends expected to impact growth include broader use of AI-enhanced imaging analysis, predictive models that predict disease progression, integration of AI into lung diagnostic methods, expansion of remote respiratory monitoring solutions, and an intensified focus on early detection of respiratory diseases.
The market size of artificial intelligence (AI) in respiratory diseases has grown steadily in recent years. It will grow from $7.98 billion in 2025 to $8.38 billion in 2026 at a compound annual growth rate (CAGR) of 4.9%. The growth in this historical period can be attributed to the rising incidence of respiratory diseases, increased use of CT and MRI, increasing digitization of healthcare records, early adoption of AI-assisted diagnosis, and expanding diagnostic capabilities in hospitals.
Download free sample of Artificial Intelligence (AI) in Respiratory Diseases Market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13792&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR
Emerging Leaders in the Respiratory Diseases AI Market
A number of prominent companies are actively shaping the AI landscape in respiratory healthcare. These include Siemens Healthineers, Philips Healthcare, GE Healthcare, Verily Life Sciences LLC, DeepMind Health, Merative LP, Aidoc Medical, Butterfly Network, Infervision, Imagen Technologies, Caption Health, Swaasa AI, VIDA Diagnostics Inc., Enlitic, Tirona BV, ArtiQ, Icometrix, Aidence, Arterys, PneumoWave Ltd. Strengthening the diagnosis, monitoring and management of respiratory diseases.
Major acquisition to enhance digital respiratory care
In July 2023, ResMed Inc., a US-based medical equipment manufacturer focused on cloud-connected devices, acquired Somnoware, a cloud platform dedicated to improving respiratory care management and supporting hospital services at home. Although the acquisition amount was not disclosed, the move is expected to strengthen ResMed’s portfolio in sleep and respiratory care technologies. Integrating the Somnoware platform will likely improve patient data management, simplify equipment ordering, improve appointment scheduling, and enhance compliance tracking. Ultimately, these benefits should lead to better patient experiences and better health outcomes.
View the Artificial Intelligence (AI) for Respiratory Diseases market report in detail:
https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-respiratory-diseases-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR
Innovations that advance the applications of artificial intelligence in lung disease monitoring
Leading companies also offer pioneering respiratory monitoring tools, such as the N-Tidal device, which measures tidal breathing — the volume of air exchanged during regular breathing — to provide insightful data on lung function. For example, in August 2023, TidalSense, a UK-based respiratory technology company, launched the AI-powered N-Tidal system designed to diagnose and manage chronic obstructive pulmonary disease (COPD). This technology combines sensor data with artificial intelligence algorithms to accurately detect changes in lung function. Clinical trials have confirmed its accuracy, making it a promising alternative to traditional diagnostic tests. This development represents a major advance in AI-based respiratory disease assessment, providing a more patient-friendly and more efficient diagnostic approach.
Key sectors contributing to the growth of AI for respiratory diseases
The Artificial Intelligence in Respiratory Diseases market is analyzed across several important segments:
1) Photography type:
– Magnetic resonance imaging (MRI)
– Computed tomography (CT) scan.
– Electronic Patient Reported Outcomes (ePRO)
2) Signal:
– Chronic pulmonary obstruction
– Interstitial lung disease
– Pneumonia
3) End use:
– Hospitals
– Diagnostic centers
– Mobile surgical centers
– Other end users
Other detailed subcategories include:
– MRI applications such as lung imaging, chest imaging, and heart and lung imaging
Types of CT scans, including high-resolution CT (HRCT), low-dose CT, and chest CT
– ePRO functions covering symptom tracking, medication adherence monitoring, and quality of life assessments
These sectors highlight the comprehensive approach to integrating AI technologies into various aspects of respiratory disease diagnosis and management, meeting diverse clinical needs and healthcare settings.
Our latest 2026 Market Report provides expanded strategic and visual information with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, charts of market hotspots, key technologies and future trend analysis, along with updated graphics and tables.
Contact us:
Business research company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia et al +44 7882 955267 and +91 8897263534,
Email us at [email protected].
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn more about the business research company
With more than 30,000 reports from 27 industries covering more than 60 geographies, The Business Research Company has earned a reputation for providing comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead. Our flagship product, the Global Market Model (GMM), is a leading market intelligence platform that delivers comprehensive, up-to-date forecasts to support informed decision making.
This version is published on openPR.
